GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (FRA:6LP) » Definitions » EBITDA Margin %

Bolt Biotherapeutics (FRA:6LP) EBITDA Margin % : -315.40% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bolt Biotherapeutics's EBITDA for the three months ended in Mar. 2024 was €-15.30 Mil. Bolt Biotherapeutics's Revenue for the three months ended in Mar. 2024 was €4.85 Mil. Therefore, Bolt Biotherapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was -315.40%.


Bolt Biotherapeutics EBITDA Margin % Historical Data

The historical data trend for Bolt Biotherapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics EBITDA Margin % Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -14,211.86 -21,013.16 -7,270.13 -1,547.52 -943.95

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -983.17 -1,351.63 -700.93 -923.64 -315.40

Competitive Comparison of Bolt Biotherapeutics's EBITDA Margin %

For the Biotechnology subindustry, Bolt Biotherapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's EBITDA Margin % falls into.



Bolt Biotherapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bolt Biotherapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-68.172/7.222
=-943.95 %

Bolt Biotherapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-15.303/4.852
=-315.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics  (FRA:6LP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Bolt Biotherapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (FRA:6LP) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Bolt Biotherapeutics (FRA:6LP) Headlines

No Headlines